MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets
暂无分享,去创建一个
Avery S. Feit | Henry W. Long | M. Loda | Y. Zhang | Myles A Brown | M. Freedman | D. Spratt | E. Davicioni | E. Schaeffer | K. Wucherpfennig | L. Ellis | Adrienne M. Luoma | C. Morrissey | E. Corey | X. Shirley Liu | S. Weinmann | P. Cejas | Ji-Heui Seo | Yang Liu | Xintao Qiu | Yingtian Xie | M. Pomerantz | G. Zadra | N. Boufaied | Edward P. O’Connor | S. Gu | Qin Tang | Connor Bell | A. de Polo | D. Labbé | Tarek Hallal | W. Alahmadi | J. Larocque | Sudeepa Syamala | R. Jeffrey Karnes | Yi Zhang | A. Feit | Myles A. Brown | Nadia Boufaied
[1] Len Taing,et al. CoBRA: Containerized Bioinformatics workflow for Reproducible ChIP/ATAC-seq Analysis - from differential peak calling to pathway analysis , 2020, bioRxiv.
[2] M. Rubin,et al. A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance , 2020, Nature Cancer.
[3] Henry W. Long,et al. Prostate cancer reactivates developmental epigenomic programs during metastatic progression , 2020, Nature Genetics.
[4] Simran K. Sandhu,et al. Urethral luminal epithelia are castration‐insensitive cells of the proximal prostate , 2020, The Prostate.
[5] D. Pe’er,et al. Regenerative potential of prostate luminal cells revealed by single-cell analysis , 2020, Science.
[6] F. Jamali,et al. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. , 2002, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[7] Yuan Wang,et al. Single-Cell Map of Diverse Immune Phenotypes in the Metastatic Brain Tumor Microenvironment of Non Small Cell Lung Cancer , 2019, bioRxiv.
[8] Mihai I Truica,et al. Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. , 2019, Cancer cell.
[9] P. Nelson,et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. , 2019, The Journal of clinical investigation.
[10] Jacob D. Jaffe,et al. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program , 2019, Nature Communications.
[11] A. Chinnaiyan,et al. Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer , 2019, Clinical Cancer Research.
[12] D. Strand,et al. Expansion of Luminal Progenitor Cells in the Aging Mouse and Human Prostate , 2019, Cell reports.
[13] Yi Mi Wu,et al. Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.
[14] R. Vessella,et al. A Positive Role of c-Myc in Regulating Androgen Receptor and its Splice Variants in Prostate Cancer , 2019, Oncogene.
[15] A. Jemal,et al. Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[16] Dharmesh D. Bhuva,et al. Single sample scoring of molecular phenotypes , 2018, BMC Bioinformatics.
[17] Myles A Brown,et al. Transcriptional Regulation in Prostate Cancer. , 2018, Cold Spring Harbor perspectives in medicine.
[18] Ambrose J. Carr,et al. Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment , 2018, Cell.
[19] Jonathan Scolnick,et al. Faculty Opinions recommendation of Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[20] K. D. Sørensen,et al. Germline variation at 8q24 and prostate cancer risk in men of European ancestry , 2018, Nature Communications.
[21] A. Shilatifard,et al. Born to run: control of transcription elongation by RNA polymerase II , 2018, Nature Reviews Molecular Cell Biology.
[22] Bo Li,et al. VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis , 2018, BMC Bioinformatics.
[23] Paul Hoffman,et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.
[24] Jun Luo,et al. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9® to Suppress Enzalutamide-resistant Prostate Cancer Progression. , 2017, European urology.
[25] P. Stopka,et al. On the tear proteome of the house mouse (Mus musculus musculus) in relation to chemical signalling , 2017, PeerJ.
[26] Bernat Gel,et al. karyoploteR: an R/Bioconductor package to plot customizable genomes displaying arbitrary data , 2017, bioRxiv.
[27] Stefan J. Barfeld,et al. c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks , 2017, EBioMedicine.
[28] B. Trock,et al. Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] P. Nelson,et al. LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics , 2017, The Prostate.
[30] Kaitlyn M. Gayvert,et al. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. , 2016, Cancer cell.
[31] Tao Liu,et al. ChiLin: a comprehensive ChIP-seq and DNase-seq quality control and analysis pipeline , 2016, BMC Bioinformatics.
[32] Roland Eils,et al. Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..
[33] Susanne Mandrup,et al. Cofactor squelching: Artifact or fact? , 2016, BioEssays : news and reviews in molecular, cellular and developmental biology.
[34] Kati Räsänen,et al. Emerging Roles of SPINK1 in Cancer. , 2016, Clinical chemistry.
[35] J. Shendure,et al. Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer , 2016, Nature Medicine.
[36] Gianluca Bontempi,et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.
[37] Hamid Bolouri,et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer , 2016 .
[38] J. Mesirov,et al. The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .
[39] V. Arora,et al. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer , 2015, Nature Reviews Cancer.
[40] Steven J. M. Jones,et al. The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.
[41] Henry W. Long,et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis , 2015, Nature Genetics.
[42] J. Mesirov,et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.
[43] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[44] W. Isaacs,et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.
[45] S. Hautaniemi,et al. Tissue‐specific pioneer factors associate with androgen receptor cistromes and transcription programs , 2014, The EMBO journal.
[46] Hanfei Sun,et al. Target analysis by integration of transcriptome and ChIP-seq data with BETA , 2013, Nature Protocols.
[47] Gang Shao,et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. , 2013, Cancer discovery.
[48] C. Dang. MYC, metabolism, cell growth, and tumorigenesis. , 2013, Cold Spring Harbor perspectives in medicine.
[49] A. Sivachenko,et al. Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.
[50] X. Liu,et al. Amplitude Modulation of Androgen Signaling by C-myc Material Supplemental , 2013 .
[51] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[52] Stephen R. Piccolo,et al. A single-sample microarray normalization method to facilitate personalized-medicine workflows. , 2012, Genomics.
[53] E. Klein,et al. High-Grade Prostatic Intraepithelial Neoplasia , 2012, Korean journal of urology.
[54] Timothy J. Durham,et al. Systematic analysis of chromatin state dynamics in nine human cell types , 2011, Nature.
[55] Matthew L. Freedman,et al. Analysis of the 10q11 Cancer Risk Locus Implicates MSMB and NCOA4 in Human Prostate Tumorigenesis , 2010, PLoS genetics.
[56] M. Nóbrega,et al. An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer. , 2010, Genome research.
[57] W. Gerald,et al. Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3 , 2010, Prostate Cancer and Prostatic Diseases.
[58] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[59] R. Matusik,et al. Characterization of cis elements of the probasin promoter necessary for prostate‐specific gene expression , 2010, The Prostate.
[60] C. Glass,et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.
[61] Cole Trapnell,et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. , 2010, Nature biotechnology.
[62] Cole Trapnell,et al. Role of Rodent Secondary Motor Cortex in Value-based Action Selection Nih Public Access Author Manuscript , 2006 .
[63] D. Felsher,et al. MYC as a regulator of ribosome biogenesis and protein synthesis , 2010, Nature Reviews Cancer.
[64] Christopher B. Burge,et al. c-Myc Regulates Transcriptional Pause Release , 2010, Cell.
[65] P. Pandolfi,et al. Prostate Cancer Progression , 2010 .
[66] Christopher A. Haiman,et al. The 8q24 cancer risk variant rs6983267 demonstrates long-range interaction with MYC in colorectal cancer , 2009, Nature Genetics.
[67] Cole Trapnell,et al. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.
[68] Clifford A. Meyer,et al. Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.
[69] Jun Luo,et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis , 2008, Modern Pathology.
[70] M. Gross,et al. Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. , 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.
[71] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[72] D. Bostwick,et al. High-grade prostatic intraepithelial neoplasia. , 2004, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[73] T. Graeber,et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. , 2003, Cancer cell.
[74] C. Bieberich,et al. Ventral prostate predominant l, a novel mouse gene expressed exclusively in the prostate * , 2002, The Prostate.
[75] R. Matusik,et al. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. , 2000, Endocrinology.
[76] F. Alt,et al. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. , 2000, Genes & development.
[77] M. Pagano,et al. Survival analysis. , 1996, Nutrition.
[78] Berthold Lausen,et al. Maximally selected rank statistics , 1992 .
[79] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[80] A. W. Harris,et al. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells , 1988, The Journal of experimental medicine.
[81] S. Liao,et al. Androgen-sensitive spermine-binding protein of rat ventral prostate. Purification of the protein and characterization of the hormonal effect. , 1979, The Biochemical journal.
[82] C. Huggins,et al. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.
[83] C. Huggins,et al. STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND , 1941 .
[84] J. W. White. II. The Present Position of the Surgery of the Hypertrophied Prostate. , 1904, Annals of surgery.
[85] White Jw. I. The Results of Double Castration in Hypertrophy of the Prostate. , 1895 .
[86] J. W. White. II. The Present Position of the Surgery of the Hypertrophied Prostate. , 1893, Annals of surgery.